Watch the October 23 webcast for any disclosed efficacy or safety signals from the unblinded HERO/OLE data; the path to a new Phase 3 design and potential registration timeline will be key catalysts.
Price Chart
Executive Summary
Aardvark Therapeutics announced that the FDA has lifted the clinical hold on its IND for ARD-101 for hyperphagia in Prader-Willi Syndrome, allowing clinical development to resume. The hold was placed in May 2026 after reversible ECG changes were observed in a separate healthy-volunteer study; a subsequent thorough ECG study at 200 mg and 400 mg BID showed no cardiac events. The company plans to host a webcast on October 23, 2026 to review exploratory data from the terminated Phase 3 HERO and OLE trials.
Key Facts
- FDA lifted clinical hold on ARD-101 IND for hyperphagia in Prader-Willi Syndrome as of October 22, 2026
- Clinical hold was placed in May 2026 after reversible ECG changes in a separate healthy-volunteer study
- Aardvark completed a thorough ECG study at 200 mg and 400 mg BID with no cardiac events observed
- Company will host a webcast on October 23, 2026 to review available exploratory data from the terminated Phase 3 HERO and OLE trials
- Aardvark plans to resume clinical development after additional FDA alignment on Phase 3 trial design
Financial Impact
No financial figures provided; the clinical hold removal removes a binary overhang on the sole pipeline asset (ARD-101) for PWS
Risk Factors
- FDA may not agree with proposed Phase 3 program or may require additional studies
- HERO and OLE trials were terminated early and not powered to assess efficacy, limiting data interpretability
- Clinical hold removal does not guarantee eventual approval; safety or efficacy issues could re-emerge
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-428943 |
| Document: ck0001774857-ex99_1.htm | 0001193125-26-428943 |
| Document: 0001193125-26-428943-index-headers.html | 0001193125-26-428943 |
| Document: 0001193125-26-428943-index.html | 0001193125-26-428943 |
| Document: 0001193125-26-428943.txt | 0001193125-26-428943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers